C-reactive Protein Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Assay Type (Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay, Others), By Detection Range (hs-CRP, Conventional CRP, cCRP), By Disease Area (Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, Others), By End-

Market Overview

Global C-reactive Protein Testing Market has valued at USD 1601.01 Million in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 2.16% through 2028. C-reactive Protein Testing is a laboratory test that measures the level of C-reactive protein in the blood. C-reactive protein is a type of protein that is produced by the liver in response to inflammation in the body. It is part of the body's natural immune response to infection, injury, or other forms of inflammation. CRP testing is typically done through a blood sample, and the results are reported as milligrams of CRP per liter of blood (mg/L). Normal CRP levels are generally low, and elevated levels may indicate ongoing inflammation or infection. However, it's important to note that CRP levels can also be influenced by other factors, such as smoking, obesity, and certain medications. CRP testing is commonly used as a marker of inflammation in various medical settings. It is often ordered by healthcare providers to help diagnose and monitor a wide range of conditions, such asInfections, Autoimmune Diseases, Cardiovascular Diseases, Trauma or Surgery, Monitoring Treatment.

Key Market Drivers

Growing Incidence of Inflammatory and Infectious Diseases

The growing incidence of inflammatory and infectious diseases contributes significantly to the growth of the global C-reactive protein (CRP) testing market. Inflammatory and infectious diseases often involve an immune response, which can lead to elevated CRP levels in the bloodstream. As the incidence of these diseases rises, healthcare providers need reliable diagnostic tools to detect and monitor the presence of inflammation. CRP testing offers a convenient and effective way to assess inflammation levels, aiding in the diagnosis and management of various conditions. Timely detection of inflammation is crucial for effective disease management and prevention of complications. CRP testing allows for early identification of inflammation, enabling healthcare professionals to intervene before the condition worsens. This aligns with the broader trend of focusing on preventive healthcare and early disease detection. Many chronic diseases, such as rheumatoid arthritis, inflammatory bowel disease, and certain autoimmune disorders, involve ongoing inflammation. CRP testing helps clinicians monitor the severity of inflammation and adjust treatment plans accordingly. As the prevalence of these chronic conditions increases, the demand for CRP testing as a monitoring tool also grows. Inflammations is a recognized risk factor for cardiovascular diseases (CVD), including heart attacks and strokes. Elevated CRP levels have been associated with increased CVD risk. Healthcare providers use CRP testing as part of an overall risk assessment for CVD, which can influence treatment decisions and lifestyle recommendations. CRP levels can rise in response to infections, both bacterial and viral. Monitoring CRP levels can aid in tracking the progression of infections, evaluating the effectiveness of antimicrobial therapies, and determining when a patient is recovering. The increasing prevalence of inflammatory and infectious diseases has prompted extensive research into the role of inflammation in various health conditions. This research generates insights into the relationship between CRP levels and disease outcomes, further highlighting the importance of CRP testing in clinical practice.

Increasing Awareness of Preventive Healthcare

The increasing awareness of preventive healthcare has a significant impact on driving the growth of the global C-reactive protein (CRP) testing market. Preventive healthcare focuses on identifying health issues at an early stage, even before symptoms become apparent. CRP testing serves as a valuable tool in this context by detecting low-grade inflammation that might not be clinically evident yet. Early detection of inflammation through CRP testing enables timely intervention and management, potentially preventing the progression of underlying diseases. Preventive healthcare often involves assessing an individual's risk of developing certain diseases. CRP testing can contribute to risk stratification by providing information about a person's inflammation levels. Elevated CRP levels are associated with an increased risk of conditions such as cardiovascular diseases, making CRP testing a valuable component of risk assessment protocols. The awareness of preventive healthcare promotes the idea of personalized health plans tailored to an individual's specific risk factors and health needs. CRP testing adds an objective biomarker to guide these personalized plans, helping healthcare providers design interventions and lifestyle modifications that address inflammation-related risks. Preventive healthcare often emphasizes lifestyle modifications to promote better health outcomes. CRP testing results can serve as a tangible marker that motivates individuals to make healthier choices, such as improving their diet, increasing physical activity, and quitting smoking. The availability of CRP testing supports educational efforts aimed at empowering individuals to take control of their health. Public health initiatives and screening programs are a part of preventive healthcare efforts. CRP testing can be integrated into these programs to identify individuals at risk of inflammatory conditions and related diseases. This proactive approach can lead to early interventions, reducing the burden of chronic diseases on healthcare systems.

Increasing Geriatric Population And Associated Chronic Diseases

The increasing geriatric population and the associated prevalence of chronic diseases play a significant role in driving the growth of the global C-reactive protein (CRP) testing market. Aging is associated with changes in the immune system, making older adults more susceptible to inflammation. Chronic low-grade inflammation, known as inflammation, is common in the elderly and contributes to the development of various age-related chronic diseases. CRP testing is a valuable tool to assess and monitor this chronic inflammation, providing insights into disease risk and progression. The geriatric population is more prone to chronic diseases such as cardiovascular diseases, diabetes, osteoarthritis, and certain cancers. CRP testing helps healthcare providers evaluate the inflammatory component of these diseases, aiding in their diagnosis, management, and monitoring. Older adults are at an increased risk of cardiovascular diseases, and inflammation is a key factor in their pathogenesis. CRP testing is used to assess cardiovascular risk and guide treatment decisions, particularly in the elderly population, where preventive measures are crucial. Elderly individuals often have multiple chronic conditions simultaneously. CRP testing provides insights into the overall inflammatory status, helping healthcare providers manage multimorbidity more effectively and make informed treatment choices. Older adults are more susceptible to infections due to age-related changes in the immune system. CRP levels can rise in response to infections, aiding in the assessment and monitoring of infectious diseases, which can have more serious consequences in the elderly. Preventive healthcare in the geriatric population emphasizes early detection and intervention to prevent disease progression and improve quality of life. CRP testing contributes to this approach by detecting inflammation at an early stage, allowing for timely interventions and personalized treatment plans. Geriatric care facilities and long-term care settings often serve individuals with complex health needs. CRP testing is a valuable tool in these settings for monitoring residents' health, identifying potential infections, and managing chronic diseases.

Key Market Challenges

Non-Specificity of Elevated CRP

The non-specificity of elevated C-reactive protein (CRP) levels poses a challenge to the global CRP testing market primarily because it can lead to uncertainties in diagnosis and treatment decisions. Elevated CRP levels indicate the presence of inflammation, but they do not provide specific information about the underlying cause of inflammation. This lack of specificity can lead to diagnostic confusion, as healthcare providers may need to conduct additional tests to pinpoint the exact condition causing the elevated CRP. As a result, there might be delays in diagnosing the actual underlying disease. The non-specific nature of CRP elevation can lead to situations where CRP testing is ordered excessively or inappropriately, contributing to unnecessary healthcare costs and resource utilization. Healthcare providers may order CRP tests in cases where inflammation is present but not clinically significant, potentially leading to overdiagnosis and overuse of healthcare services.

Varied Reference Ranges

Different laboratories and healthcare facilities may use varying reference ranges for defining normal, elevated, and high CRP levels. This inconsistency can lead to confusion among healthcare providers and patients when interpreting CRP test results. A value that is considered normal in one setting might be categorized as elevated in another, affecting clinical decision-making. Varied reference ranges can create uncertainty about whether a given CRP level is within a normal range or indicative of inflammation. This ambiguity can lead to challenges in diagnosing inflammatory conditions accurately, potentially delaying appropriate treatment and management. Efforts to establish standardized reference ranges for CRP levels can help ensure consistent interpretation across different settings and laboratories. Professional medical organizations can provide guidelines and recommendations for interpreting CRP test results and defining reference ranges based on clinical evidence and consensus.

Influence of External Factors

The influence of external factors on C-reactive protein (CRP) levels can pose challenges to the global CRP testing market, affecting the accuracy, interpretation, and clinical utility of CRP test results. CRP levels can be affected by various external factors, such as smoking, obesity, and medications. These factors can lead to elevated CRP levels even in the absence of significant inflammation. Healthcare providers may misinterpret elevated CRP levels as indicative of inflammation when they are actually driven by external influences. When external factors contribute to elevated CRP levels, healthcare providers may face challenges in distinguishing between true inflammation and non-inflammatory causes of CRP elevation. This complexity can lead to difficulties in accurately diagnosing and managing inflammatory conditions. External factors can lead to false positive or false negative CRP test results. For example, a patient with inflammation might have normal CRP levels due to the influence of certain medications. Conversely, a patient with elevated CRP levels due to non-inflammatory factors might be wrongly considered at risk for inflammation-related conditions. External factors can lead to fluctuations in CRP levels over time, even in the absence of changes in disease status. This inconsistency can make it challenging to monitor disease progression accurately and make informed treatment decisions.

Key Market Trends

Rising Demand for Personalized Medicine

The rising demand for personalized medicine is a significant trend in the global C-reactive protein (CRP) testing market, influencing its growth and application. Personalized medicine aims to tailor medical treatment and interventions to individual patients based on their unique characteristics, including genetic makeup, lifestyle, and biomarker profiles.

Segmental Insights

Assay Type

In 2022, the C-reactive Protein Testing market was dominated by the immunoturbidimetric assays segment and is predicted to continue expanding over the coming years.

Detection Range Insight

In 2022, the C-reactive Protein Testing market was dominated by hs-CRP 3 segment segment and is predicted to continue expanding over the coming years.

Disease Area Insight

In 2022, the C-reactive Protein Testing market was dominated by cardiovascular diseases (CVD) segment and is predicted to continue expanding over the coming years.

End-Use Industry Insights

In 2022, the C-reactive Protein Testing market was dominated by hospital segment and is predicted to continue expanding over the coming years.

Regional Insights

The North America region has established itself as the leader in the Global C-reactive Protein Testing Market.

Recent Developments

• InSeptember 2022, Roche to acquire biopharma firm Good therapeutics for USD 250 m.Roche’s IL-2 drug business is focused on developing conditionally active drugsbased on innovative IL-2 drug technology that are PD-1 regulated. In thecontext of the acquisition, Roche obtains the rights to an IL-2 drug that isconditionally active and PD-1 regulated, which is called the Good TherapeuticProgramme. Roche also obtains the exclusive use of the platform technologydeveloped by Good Therapeutic for the development of IL-2 drug therapy that isPD-1 regulated and receptor agonist therapy.
• InFebruary 2023, Danaher Corporation Announces the Formation of VeraltoCorporation (“Veralto” or the “Company”) Danaher Corporation has announced theformation of a separate public company, Veralto Corporation, which Danaherplans to initiate in the fourth quarters of 2023. Veralto will consist of animpressive portfolio of leading brands in Danaher’s EAS segment, includingHach ChemTreat Trojan OTC HydroMet McCreter Water Quality Platform VideojetEsko X-rite Pantone Linx Product Identification Platform.
• InApril 2023, Siemens healthineers continues to expand its manufacturingfootprint in India, with the inauguration of an MRI facility in Bengaluru underthe government of India's PLI scheme.

Key Market Players

• ThermoFisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd.
• DanaherCorp
• QuestDiagnostics
• SiemensHealthineers AG
• AbbottLaboratories Inc.
• MerckKGaAA
• ZoetisInc.
• OrthoClinical Diagnostics
• GeteinBiotech, Inc.